

# Stefan Leucht

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4757850/publications.pdf>

Version: 2024-02-01

435  
papers

41,925  
citations

2322

98  
h-index

2828

191  
g-index

484  
all docs

484  
docs citations

484  
times ranked

26179  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. <i>Lancet, The</i> , 2013, 382, 951-962.	13.7	2,094
2	Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2018, 391, 1357-1366.	13.7	2,076
3	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. <i>World Psychiatry</i> , 2011, 10, 52-77.	10.4	1,767
4	Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. <i>Lancet, The</i> , 2009, 373, 31-41.	13.7	1,663
5	What does the PANSS mean?. <i>Schizophrenia Research</i> , 2005, 79, 231-238.	2.0	1,083
6	Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2019, 394, 939-951.	13.7	1,050
7	Clinical implications of Brief Psychiatric Rating Scale scores. <i>British Journal of Psychiatry</i> , 2005, 187, 366-371.	2.8	799
8	Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. <i>Schizophrenia Research</i> , 1999, 35, 51-68.	2.0	777
9	Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. <i>Lancet, The</i> , 2012, 379, 2063-2071.	13.7	742
10	New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. <i>Lancet, The</i> , 2003, 361, 1581-1589.	13.7	667
11	Lower Risk for Tardive Dyskinesia Associated With Second-Generation Antipsychotics: A Systematic Review of 1-Year Studies. <i>American Journal of Psychiatry</i> , 2004, 161, 414-425.	7.2	653
12	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. <i>World Psychiatry</i> , 2011, 10, 138-151.	10.4	631
13	Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. <i>Schizophrenia Research</i> , 2010, 123, 225-233.	2.0	577
14	The Effect of Family Interventions on Relapse and Rehospitalization in Schizophrenia--A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2001, 27, 73-92.	4.3	571
15	Physical illness and schizophrenia: a review of the literature. <i>Acta Psychiatrica Scandinavica</i> , 2007, 116, 317-333.	4.5	545
16	Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. <i>Lancet, The</i> , 2016, 388, 881-890.	13.7	513
17	Amisulpride, an Unusual "Atypical" Antipsychotic: A Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Psychiatry</i> , 2002, 159, 180-190.	7.2	455
18	Relapse Prevention in Schizophrenia With New-Generation Antipsychotics: A Systematic Review and Exploratory Meta-Analysis of Randomized, Controlled Trials. <i>American Journal of Psychiatry</i> , 2003, 160, 1209-1222.	7.2	455

#	ARTICLE	IF	CITATIONS
19	A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. <i>American Journal of Psychiatry</i> , 2009, 166, 152-163.	7.2	453
20	How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. <i>Molecular Psychiatry</i> , 2009, 14, 429-447.	7.9	428
21	Dose Equivalents for Antipsychotic Drugs: The DDD Method: Table 1.. <i>Schizophrenia Bulletin</i> , 2016, 42, S90-S94.	4.3	428
22	Living systematic review: 1. Introduction—the why, what, when, and how. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 23-30.	5.0	406
23	Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics. <i>American Journal of Psychiatry</i> , 2006, 163, 185-194.	7.2	401
24	Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials. <i>Schizophrenia Research</i> , 2011, 127, 83-92.	2.0	397
25	Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2009, 35, 443-457.	4.3	360
26	Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors. <i>American Journal of Psychiatry</i> , 2017, 174, 927-942.	7.2	338
27	Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. <i>British Journal of Psychiatry</i> , 2012, 200, 97-106.	2.8	332
28	Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials. <i>Schizophrenia Bulletin</i> , 2014, 40, 192-213.	4.3	332
29	Acamprosate supports abstinence, Naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. <i>Journal of Psychopharmacology</i> , 2008, 22, 11-23.	4.0	288
30	Efficacy of Anti-inflammatory Agents to Improve Symptoms in Patients With Schizophrenia: An Update. <i>Schizophrenia Bulletin</i> , 2014, 40, 181-191.	4.3	288
31	Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2014, 1, 351-359.	7.4	280
32	Dose Equivalents for Second-Generation Antipsychotics: The Minimum Effective Dose Method. <i>Schizophrenia Bulletin</i> , 2014, 40, 314-326.	4.3	277
33	Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. <i>Journal of Affective Disorders</i> , 2015, 180, 179-184.	4.1	267
34	Shared decision making for in-patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006, 114, 265-273.	4.5	265
35	Linking the PANSS, BPRS, and CGI: Clinical Implications. <i>Neuropsychopharmacology</i> , 2006, 31, 2318-2325.	5.4	257
36	Living systematic reviews: 2. Combining human and machine effort. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 31-37.	5.0	246

#	ARTICLE	IF	CITATIONS
37	Efficacy of Pharmacotherapy and Psychotherapy for Adult Psychiatric Disorders. <i>JAMA Psychiatry</i> , 2014, 71, 706.	11.0	244
38	Standardized remission criteria in schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 91-95.	4.5	238
39	Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 199.	11.0	235
40	Shared decision making in psychiatry. <i>Acta Psychiatrica Scandinavica</i> , 2003, 107, 403-409.	4.5	233
41	Acamprosate for alcohol dependence. <i>The Cochrane Library</i> , 2010, , CD004332.	2.8	232
42	Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons. <i>Schizophrenia Bulletin</i> , 2012, 38, 167-177.	4.3	229
43	Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials. <i>Neuropsychopharmacology</i> , 2011, 36, 375-389.	5.4	222
44	Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended. <i>Biological Psychiatry</i> , 2005, 57, 1543-1549.	1.3	218
45	Second-generation antipsychotic effect on cognition in patients with schizophrenia—a meta-analysis of randomized clinical trials. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 185-196.	4.5	216
46	Second-Generation Antipsychotic Agents in the Treatment of Acute Mania. <i>Archives of General Psychiatry</i> , 2007, 64, 442.	12.3	204
47	Do Patients With Schizophrenia Wish to Be Involved in Decisions About Their Medical Treatment?. <i>American Journal of Psychiatry</i> , 2005, 162, 2382-2384.	7.2	203
48	Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. <i>Schizophrenia Bulletin</i> , 2015, 41, 1397-1402.	4.3	198
49	Comparative Efficacy and Acceptability of 21 Antidepressant Drugs for the Acute Treatment of Adults With Major Depressive Disorder: A Systematic Review and Network Meta-Analysis. <i>Focus (American Journal of Psychiatry)</i> , 2017, 115, 114-127.	10.7	187
50	Is the Superior Efficacy of New Generation Antipsychotics an Artifact of LOCF?. <i>Schizophrenia Bulletin</i> , 2006, 33, 183-191.	4.3	185
51	Living systematic reviews: 4. Living guideline recommendations. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 47-53.	5.0	184
52	Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. <i>Lancet Psychiatry</i> , 2019, 6, 601-609.	7.4	184
53	Detecting Neuroimaging Biomarkers for Schizophrenia: A Meta-Analysis of Multivariate Pattern Recognition Studies. <i>Neuropsychopharmacology</i> , 2015, 40, 1742-1751.	5.4	182
54	Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2020, 7, 581-601.	7.4	176

#	ARTICLE	IF	CITATIONS
55	Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 7-14.	4.5	173
56	Defining "Response"™ in Antipsychotic Drug Trials: Recommendations for the Use of Scale-Derived Cutoffs. <i>Neuropsychopharmacology</i> , 2007, 32, 1903-1910.	5.4	171
57	Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. <i>American Journal of Psychiatry</i> , 2016, 173, 876-886.	7.2	167
58	Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 1124-1130.	5.0	166
59	Amitriptyline or Not, That Is the Question: Pharmacogenetic Testing of CYP2D6 and CYP2C19 Identifies Patients with Low or High Risk for Side Effects in Amitriptyline Therapy. <i>Clinical Chemistry</i> , 2005, 51, 376-385.	3.2	162
60	Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. <i>Lancet Psychiatry</i> , 2016, 3, 1059-1066.	7.4	161
61	Dropout rates in randomised antipsychotic drug trials. <i>Psychopharmacology</i> , 2001, 155, 230-233.	3.1	156
62	Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. <i>World Psychiatry</i> , 2017, 16, 77-89.	10.4	156
63	Second-generation antipsychotics for schizophrenia: can we resolve the conflict?. <i>Psychological Medicine</i> , 2009, 39, 1591.	4.5	155
64	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2012, , CD008016.	2.8	154
65	Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia. <i>JAMA Psychiatry</i> , 2017, 74, 675.	11.0	153
66	What does the HAMD mean?. <i>Journal of Affective Disorders</i> , 2013, 148, 243-248.	4.1	152
67	Early Improvement As a Predictor of Later Response to Antipsychotics in Schizophrenia: A Diagnostic Test Review. <i>American Journal of Psychiatry</i> , 2015, 172, 617-629.	7.2	150
68	Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later. <i>Dialogues in Clinical Neuroscience</i> , 2010, 12, 393-407.	3.7	146
69	Shared Decision Making and Long-Term Outcome in Schizophrenia Treatment. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 992-997.	2.2	145
70	Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review. <i>Schizophrenia Bulletin</i> , 2012, 38, 1003-1011.	4.3	144
71	Multisite prediction of 4-week and 52-week treatment outcomes in patients with first-episode psychosis: a machine learning approach. <i>Lancet Psychiatry</i> , 2016, 3, 935-946.	7.4	144
72	Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 625-639.	3.2	143

#	ARTICLE	IF	CITATIONS
73	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMISE): a three-phase switching study. <i>Lancet Psychiatry</i> , 2018, 5, 797-807.	7.4	141
74	Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis. <i>BMJ Open</i> , 2016, 6, e010919.	1.9	139
75	Effectiveness of Long-Acting Injectable vs Oral Antipsychotics in Patients With Schizophrenia: A Meta-analysis of Prospective and Retrospective Cohort Studies. <i>Schizophrenia Bulletin</i> , 2018, 44, 603-619.	4.3	137
76	Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia. <i>American Journal of Psychiatry</i> , 2020, 177, 342-353.	7.2	137
77	Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. <i>Molecular Psychiatry</i> , 2013, 18, 53-66.	7.9	136
78	Network meta-analyses should be the highest level of evidence in treatment guidelines. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 477-480.	3.2	133
79	Attitudes of Psychiatrists Toward Antipsychotic Depot Medication. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1948-1953.	2.2	132
80	Clozapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006633.	2.8	130
81	Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate Metabolizers. <i>Clinical Chemistry</i> , 2004, 50, 1623-1633.	3.2	126
82	Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and Meta-Analysis. <i>Biological Psychiatry</i> , 2011, 69, 495-503.	1.3	126
83	Advantages and disadvantages of combination treatment with antipsychotics. <i>European Neuropsychopharmacology</i> , 2009, 19, 520-532.	0.7	125
84	The Concepts of Remission and Recovery in Schizophrenia. <i>Pharmacopsychiatry</i> , 2006, 39, 161-170.	3.3	123
85	Quetiapine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006625.		122
86	Evidence-based guidelines for interpretation of the Panic Disorder Severity Scale. <i>Depression and Anxiety</i> , 2009, 26, 922-929.	4.1	120
87	Olanzapine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006654.	2.8	120
88	How to Obtain NNT from Cohen's d: Comparison of Two Methods. <i>PLoS ONE</i> , 2011, 6, e19070.	2.5	120
89	Psychological interventions to reduce positive symptoms in schizophrenia: systematic review and network meta-analysis. <i>World Psychiatry</i> , 2018, 17, 316-329.	10.4	119
90	Early Prediction of Antipsychotic Nonresponse Among Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 352-360.	2.2	118

#	ARTICLE	IF	CITATIONS
91	Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. <i>World Psychiatry</i> , 2018, 17, 330-340.	10.4	117
92	The Relative Sensitivity of the Clinical Global Impressions Scale and the Brief Psychiatric Rating Scale in Antipsychotic Drug Trials. <i>Neuropsychopharmacology</i> , 2006, 31, 406-412.	5.4	114
93	Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. <i>Lancet Psychiatry</i> , 2021, 8, 969-980.	7.4	114
94	Second-generation antipsychotics and constipation: A review of the literature. <i>European Psychiatry</i> , 2011, 26, 34-44.	0.2	113
95	Measurements of Response, Remission, and Recovery in Schizophrenia and Examples for Their Clinical Application. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 8-14.	2.2	113
96	The Longitudinal Course of Schizophrenia Across the Lifespan. <i>Harvard Review of Psychiatry</i> , 2016, 24, 118-128.	2.1	112
97	Combining randomized and non-randomized evidence in network meta-analysis. <i>Statistics in Medicine</i> , 2017, 36, 1210-1226.	1.6	110
98	Auditory hallucinations across the lifespan: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2018, 48, 879-888.	4.5	110
99	Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI. <i>Schizophrenia Research</i> , 2008, 98, 318-322.	2.0	103
100	Living systematic reviews: 3. Statistical methods for updating meta-analyses. <i>Journal of Clinical Epidemiology</i> , 2017, 91, 38-46.	5.0	102
101	The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 12, 5-19.	2.2	102
102	Opioid antagonists for alcohol dependence. <i>The Cochrane Library</i> , 0, .	2.8	101
103	Equipercntile linking of the BPRS and the PANSS. <i>European Neuropsychopharmacology</i> , 2013, 23, 956-959.	0.7	101
104	Antipsychotic drugs for the acute treatment of patients with a first episode of schizophrenia: a systematic review with pairwise and network meta-analyses. <i>Lancet Psychiatry</i> , 2017, 4, 694-705.	7.4	97
105	Initial Severity of Schizophrenia and Efficacy of Antipsychotics. <i>JAMA Psychiatry</i> , 2015, 72, 14.	11.0	94
106	Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. <i>European Neuropsychopharmacology</i> , 2018, 28, 659-674.	0.7	93
107	Specific Substantial Dysconnectivity in Schizophrenia: A Transdiagnostic Multimodal Meta-analysis of Resting-State Functional and Structural Magnetic Resonance Imaging Studies. <i>Biological Psychiatry</i> , 2019, 85, 573-583.	1.3	93
108	How well do patients with a first episode of schizophrenia respond to antipsychotics: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2017, 27, 835-844.	0.7	92

#	ARTICLE	IF	CITATIONS
109	Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. <i>Clinica Chimica Acta</i> , 2001, 308, 33-41.	1.1	91
110	Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure. <i>JAMA Psychiatry</i> , 2021, 78, 270.	11.0	91
111	Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome. <i>Pharmacogenomics Journal</i> , 2010, 10, 20-29.	2.0	90
112	Pharmacotherapy of treatment-resistant schizophrenia: a clinical perspective. <i>Evidence-Based Mental Health</i> , 2014, 17, 33-37.	4.5	89
113	Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. <i>Lancet, The</i> , 2022, 399, 824-836.	13.7	88
114	The attitude of patients towards antipsychotic depot treatment. <i>International Clinical Psychopharmacology</i> , 2007, 22, 275-282.	1.7	87
115	Evidence-based pharmacotherapy of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2011, 14, 269-284.	2.1	87
116	Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study. <i>BMC Gastroenterology</i> , 2011, 11, 17.	2.0	86
117	Personality disorders and violence. <i>Current Opinion in Psychiatry</i> , 2008, 21, 84-92.	6.3	83
118	Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials. <i>Schizophrenia Research</i> , 2005, 80, 85-97.	2.0	81
119	Second-generation antipsychotics for major depressive disorder and dysthymia. <i>The Cochrane Library</i> , 2010, , CD008121.	2.8	78
120	How effective are common medications: a perspective based on meta-analyses of major drugs. <i>BMC Medicine</i> , 2015, 13, 253.	5.5	77
121	Methodological Issues in Current Antipsychotic Drug Trials. <i>Schizophrenia Bulletin</i> , 2007, 34, 275-285.	4.3	76
122	Correlation between amygdala volume and age in bipolar disorder – A systematic review and meta-analysis of structural MRI studies. <i>Psychiatry Research - Neuroimaging</i> , 2010, 182, 1-8.	1.8	76
123	How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials. <i>Schizophrenia Bulletin</i> , 2019, 45, 639-646.	4.3	74
124	Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials. <i>Schizophrenia Research</i> , 2004, 70, 33-37.	2.0	73
125	“How to Speak to Your Psychiatrist” Shared Decision-Making Training for Inpatients With Schizophrenia. <i>Psychiatric Services</i> , 2011, 62, 1218-1221.	2.0	73
126	Aripiprazole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD006569.	2.8	70



#	ARTICLE	IF	CITATIONS
127	Cortical Dopamine D2/D3 Receptors Are a Common Site of Action for Antipsychotic Drugs--An Original Patient Data Meta-analysis of the SPECT and PET In Vivo Receptor Imaging Literature. <i>Schizophrenia Bulletin</i> , 2009, 35, 789-797.	4.3	69
128	Risperidone versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2011, , CD006626.	2.8	69
129	Half a century of research on antipsychotics and schizophrenia: A scientometric study of hotspots, nodes, bursts, and trends. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 136, 104608.	6.1	67
130	The clinical significance of cognition-focused interventions for cognitively impaired older adults: a systematic review of randomized controlled trials. <i>International Psychogeriatrics</i> , 2011, 23, 1364-1375.	1.0	66
131	Confirmation bias: why psychiatrists stick to wrong preliminary diagnoses. <i>Psychological Medicine</i> , 2011, 41, 2651-2659.	4.5	66
132	Benzodiazepines for schizophrenia. <i>The Cochrane Library</i> , 2012, 11, CD006391.	2.8	66
133	Common pitfalls and mistakes in the set-up, analysis and interpretation of results in network meta-analysis: what clinicians should look for in a published article. <i>Evidence-Based Mental Health</i> , 2017, 20, 88-94.	4.5	66
134	The PANSS Should Be Rescaled. <i>Schizophrenia Bulletin</i> , 2010, 36, 461-462.	4.3	65
135	Valproate for schizophrenia. <i>The Cochrane Library</i> , 2016, 2016, CD004028.	2.8	65
136	Accuracy and reproducibility of the measurement of actively circulating blood volume with an integrated fiberoptic monitoring system. <i>Critical Care Medicine</i> , 1995, 23, 885-893.	0.9	64
137	Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: A meta-analysis and cochrane review of randomized controlled trials. <i>European Neuropsychopharmacology</i> , 2013, 23, 1023-1033.	0.7	63
138	Addressing missing outcome data in meta-analysis. <i>Evidence-Based Mental Health</i> , 2014, 17, 85-89.	4.5	63
139	Measurement-Based Psychiatry: Definitions of Response, Remission, Stability, and Relapse in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 1813-1814.	2.2	63
140	Translating the HAM-D into the MADRS and vice versa with equipercetile linking. <i>Journal of Affective Disorders</i> , 2018, 226, 326-331.	4.1	62
141	Benzodiazepines for schizophrenia. , 2007, , CD006391.		61
142	Efficacy and safety of clozapine in psychotic disordersâ€”a systematic quantitative meta-review. <i>Translational Psychiatry</i> , 2021, 11, 487.	4.8	61
143	Efficacy, acceptability and tolerability of antipsychotics in patients with schizophrenia and comorbid substance use. A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2019, 29, 32-45.	0.7	59
144	Second-generation antipsychotic drugs and short-term mortality: a systematic review and meta-analysis of placebo-controlled randomised controlled trials. <i>Lancet Psychiatry</i> , the, 2018, 5, 653-663.	7.4	58

#	ARTICLE	IF	CITATIONS
145	Serotonin transporter polymorphisms and side effects in antidepressant therapy – a pilot study. <i>Pharmacogenomics</i> , 2006, 7, 159-166.	1.3	57
146	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2009, , CD006569.		57
147	Psychiatrists'™ attitude to antipsychotic depot treatment in patients with first-episode schizophrenia. <i>European Psychiatry</i> , 2011, 26, 297-301.	0.2	57
148	Lithium for schizophrenia. <i>The Cochrane Library</i> , 2015, 2015, CD003834.	2.8	57
149	ABCB1 (P-Glycoprotein/MDR1) Gene G2677T/A Sequence Variation (Polymorphism): Lack of Association with Side Effects and Therapeutic Response in Depressed Inpatients Treated with Amitriptyline. <i>Clinical Chemistry</i> , 2006, 52, 893-895.	3.2	56
150	Predicting antipsychotic drug response – Replication and extension to six weeks in an international olanzapine study. <i>Schizophrenia Research</i> , 2008, 101, 312-319.	2.0	56
151	Caregivers of patients with frontotemporal lobar degeneration: a review of burden, problems, needs, and interventions. <i>International Psychogeriatrics</i> , 2012, 24, 1368-1386.	1.0	56
152	Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 281-288.	4.5	56
153	Maintenance treatment with antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2020, 2020, CD008016.	2.8	56
154	The Prevalence of Mental Illness in Homeless People in Germany. <i>Deutsches A&amp;#x0308;rztblatt International</i> , 2017, 114, 665-672.	0.9	56
155	Lithium for schizophrenia. , 2007, , CD003834.		55
156	Elaboration on the Early-Onset Hypothesis of Antipsychotic Drug Action: Treatment Response Trajectories. <i>Biological Psychiatry</i> , 2010, 68, 86-92.	1.3	55
157	Lithium for Schizophrenia Revisited. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 177-186.	2.2	55
158	Second-generation antipsychotics for anxiety disorders. <i>The Cochrane Library</i> , 2010, , CD008120.	2.8	54
159	Second-generation antipsychotics for obsessive compulsive disorder. <i>The Cochrane Library</i> , 2010, , CD008141.	2.8	54
160	Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. <i>The Cochrane Library</i> , 2015, 2015, CD009831.	2.8	52
161	Stratification and prediction of remission in first-episode psychosis patients: the OPTiMISE cohort study. <i>Translational Psychiatry</i> , 2019, 9, 20.	4.8	52
162	Antidepressants for the negative symptoms of schizophrenia. , 2006, , CD005581.		51

#	ARTICLE	IF	CITATIONS
163	Medical Decision Making in Antipsychotic Drug Choice for Schizophrenia. American Journal of Psychiatry, 2004, 161, 1301-1304.	7.2	50
164	Amisulpride – a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. International Journal of Neuropsychopharmacology, 2004, 7, S15-S20.	2.1	50
165	Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis. European Neuropsychopharmacology, 2019, 29, 1003-1022.	0.7	50
166	How to read and understand and use systematic reviews and meta-analyses. Acta Psychiatrica Scandinavica, 2009, 119, 443-450.	4.5	49
167	Identifying a system of predominant negative symptoms: Network analysis of three randomized clinical trials. Schizophrenia Research, 2016, 178, 17-22.	2.0	49
168	Equipercntile linking of scales measuring functioning and symptoms: Examining the GAF, SOFAS, CGI-S, and PANSS. European Neuropsychopharmacology, 2014, 24, 1767-1772.	0.7	48
169	Evaluation of Differences in Individual Treatment Response in Schizophrenia Spectrum Disorders. JAMA Psychiatry, 2019, 76, 1063.	11.0	48
170	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for its Methodology and a Review of the Effectiveness of Switching Antipsychotics. Schizophrenia Bulletin, 2015, 41, 549-558.	4.3	47
171	Family interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry, the, 2022, 9, 211-221.	7.4	47
172	Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials. JAMA Psychiatry, 2022, 79, 210.	11.0	47
173	On the concept of remission in schizophrenia. Psychopharmacology, 2007, 194, 453-461.	3.1	46
174	Valproate for schizophrenia. , 2008, , CD004028.		46
175	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46
176	Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination. BMC Medicine, 2015, 13, 82.	5.5	46
177	Reduced striatal dopamine synthesis capacity in patients with schizophrenia during remission of positive symptoms. Brain, 2019, 142, 1813-1826.	7.6	46
178	Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?. Pharmacogenomics Journal, 2009, 9, 395-403.	2.0	45
179	Ziprasidone versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2009, , CD006627.	2.8	45
180	What does the MADRS mean? Equipercntile linking with the CGI using a company database of mirtazapine studies. Journal of Affective Disorders, 2017, 210, 287-293.	4.1	45

#	ARTICLE	IF	CITATIONS
181	Quetiapine versus other atypical antipsychotics for schizophrenia. The Cochrane Library, 2013, , CD006625.	2.8	44
182	Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia. JAMA Psychiatry, 2021, 78, 1238.	11.0	44
183	Mid-Term and Long-Term Efficacy and Effectiveness of Antipsychotic Medications for Schizophrenia. Journal of Clinical Psychiatry, 2011, 72, 1616-1627.	2.2	43
184	Amisulpride is an ?atypical? antipsychotic associated with low weight gain. Psychopharmacology, 2004, 173, 112-115.	3.1	42
185	MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?. International Journal of Neuropsychopharmacology, 2013, 16, 2103-2109.	2.1	40
186	An approach for modelling multiple correlated outcomes in a network of interventions using odds ratios. Statistics in Medicine, 2014, 33, 2275-2287.	1.6	40
187	Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis. Molecular Autism, 2020, 11, 66.	4.9	40
188	Haloperidol versus chlorpromazine for schizophrenia. The Cochrane Library, 2008, , CD004278.	2.8	39
189	A systematic review of the clinical relevance of repetitive transcranial magnetic stimulation. Acta Psychiatrica Scandinavica, 2014, 130, 326-341.	4.5	39
190	Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatrica Scandinavica, 2018, 137, 450-458.	4.5	39
191	Translating the BDI and BDI-II into the HAMD and vice versa with equipercentile linking. Epidemiology and Psychiatric Sciences, 2020, 29, e24.	3.9	39
192	Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients. Psychopharmacology, 2000, 147, 378-383.	3.1	38
193	Carbamazepine Augmentation for Schizophrenia. Journal of Clinical Psychiatry, 2002, 63, 218-224.	2.2	38
194	Comparative remission rates of schizophrenic patients using various remission criteria. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1643-1651.	4.8	37
195	Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis. Clinical Trials, 2013, 10, 378-388.	1.6	37
196	Modeling Determinants of Medication Attitudes and Poor Adherence in Early Nonaffective Psychosis: Implications for Intervention. Schizophrenia Bulletin, 2015, 41, 584-596.	4.3	36
197	Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Molecular Autism, 2022, 13, 10.	4.9	36
198	Antipsychotic-Induced Weight Gain: Dose-Response Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin, 2022, 48, 643-654.	4.3	35

#	ARTICLE	IF	CITATIONS
199	Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials. <i>Schizophrenia Research</i> , 2011, 126, 212-219.	2.0	34
200	Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. <i>Schizophrenia Research</i> , 2013, 145, 125-127.	2.0	34
201	Dose equivalents for second generation long-acting injectable antipsychotics: The minimum effective dose method. <i>Schizophrenia Research</i> , 2018, 193, 23-28.	2.0	34
202	Biological <i>v</i>. psychosocial treatments: a myth about pharmacotherapy <i>v</i>. psychotherapy. <i>British Journal of Psychiatry</i> , 2016, 208, 309-311.	2.8	33
203	Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis. <i>Psychopharmacology</i> , 2019, 236, 545-559.	3.1	33
204	Amitriptyline versus placebo for major depressive disorder. <i>The Cochrane Library</i> , 2012, 12, CD009138.	2.8	32
205	Association of the Common MC4R rs17782313 Polymorphism With Antipsychotic-Related Weight Gain. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 74-79.	1.4	32
206	Effects of Short-Term Exercise Interventions on Behavioral and Psychological Symptoms in Patients with Dementia: A Systematic Review. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1583-1594.	2.6	32
207	Identifying the profile of optimal candidates for antipsychotic depot therapy. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1987-1993.	4.8	31
208	Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, 2014, CD009268.	2.8	31
209	CYP1A2*1D and *1F Polymorphisms Have a Significant Impact on Olanzapine Serum Concentrations. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 152-160.	2.0	31
210	How well do elderly patients with major depressive disorder respond to antidepressants: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , 2020, 20, 102.	2.6	30
211	Persistent negative symptoms in recent-onset psychosis: Relationship to treatment response and psychosocial functioning. <i>European Neuropsychopharmacology</i> , 2020, 34, 76-86.	0.7	30
212	Early improvement as a predictor of treatment response and remission in patients with schizophrenia: A pooled, post-hoc analysis from the asenapine development program. <i>Journal of Psychopharmacology</i> , 2014, 28, 387-394.	4.0	29
213	Polymorphisms in Serotonergic Pathways Influence the Outcome of Antidepressant Therapy in Psychiatric Inpatients. <i>Genetic Testing and Molecular Biomarkers</i> , 2014, 18, 20-31.	0.7	29
214	Do antipsychotic drugs lose their efficacy for relapse prevention over time?. <i>British Journal of Psychiatry</i> , 2017, 211, 127-129.	2.8	29
215	Second-generation antipsychotic drugs and short-term somatic serious adverse events: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2019, 6, 753-765.	7.4	29
216	Pharmacotherapy in the treatment of patients with borderline personality disorder. <i>International Clinical Psychopharmacology</i> , 2014, 29, 224-228.	1.7	28

#	ARTICLE	IF	CITATIONS
217	Clinical relevance of findings in trials of CBT for depression. <i>European Psychiatry</i> , 2017, 45, 207-211.	0.2	28
218	Antipsychotic drugs for elderly patients with schizophrenia: A systematic review and meta-analysis. <i>European Neuropsychopharmacology</i> , 2018, 28, 1360-1370.	0.7	28
219	Doxepin Plasma Concentrations: Is There Really a Therapeutic Range?. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 432-439.	1.4	27
220	Are the Second-generation Antipsychotics Cost-effective? A Critical Review on the Background of Different Health Systems. <i>Pharmacopsychiatry</i> , 2003, 36, 18-26.	3.3	27
221	Carbamazepine for schizophrenia. , 2007, , CD001258.		27
222	The Deceleration Capacity - a New Measure of Heart Rate Variability Evaluated in Patients With Schizophrenia and Antipsychotic Treatment. <i>European Psychiatry</i> , 2013, 28, 81-86.	0.2	27
223	Is placebo response in antidepressant trials rising or not? A reanalysis of datasets to conclude this long-lasting controversy. <i>Evidence-Based Mental Health</i> , 2018, 21, 1-3.	4.5	27
224	DRD4 48bp VNTR but not 5-HT2C Cys23Ser receptor polymorphism is related to antipsychotic-induced weight gain. <i>Pharmacogenomics Journal</i> , 2009, 9, 71-77.	2.0	26
225	Amisulpride versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006624.	2.8	26
226	How much more effective do depot antipsychotics have to be compared to oral antipsychotics before they are prescribed?. <i>European Neuropsychopharmacology</i> , 2010, 20, 276-279.	0.7	26
227	Equipercetile linking of the Brief Psychiatric Rating Scale and the Clinical Global Impression Scale in a catchment area. <i>European Neuropsychopharmacology</i> , 2012, 22, 501-505.	0.7	26
228	Carbamazepine for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD001258.	2.8	26
229	Defining therapeutic benefit for people with schizophrenia: Focus on negative symptoms. <i>Schizophrenia Research</i> , 2015, 162, 169-174.	2.0	26
230	60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response. <i>Schizophrenia Research</i> , 2018, 201, 315-323.	2.0	26
231	Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia. <i>Neuropsychopharmacology</i> , 2019, 44, 1589-1596.	5.4	26
232	Publication bias and small-study effects magnified effectiveness of antipsychotics but their relative ranking remained invariant. <i>Journal of Clinical Epidemiology</i> , 2016, 69, 161-169.	5.0	25
233	Unanswered Questions in Schizophrenia Clinical Trials. <i>Schizophrenia Bulletin</i> , 2007, 34, 302-309.	4.3	24
234	Initial symptom severity of bipolar I disorder and the efficacy of olanzapine: a meta-analysis of individual participant data from five placebo-controlled studies. <i>Lancet Psychiatry</i> , 2017, 4, 859-867.	7.4	23

#	ARTICLE	IF	CITATIONS
235	Antidepressants might work for people with major depression: where do we go from here?. <i>Lancet Psychiatry</i> , 2018, 5, 461-463.	7.4	23
236	Response rates in patients with schizophrenia and positive symptoms receiving cognitive behavioural therapy: a systematic review and single-group meta-analysis. <i>BMC Psychiatry</i> , 2018, 18, 380.	2.6	23
237	Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. <i>Neuropsychopharmacology</i> , 2019, 44, 1955-1966.	5.4	23
238	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. <i>Schizophrenia Research: Cognition</i> , 2022, 29, 100249.	1.3	23
239	Imputation of response rates from means and standard deviations in schizophrenia. <i>Schizophrenia Research</i> , 2013, 151, 209-214.	2.0	22
240	Chlorpromazine versus every other antipsychotic for schizophrenia: A systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. <i>European Neuropsychopharmacology</i> , 2014, 24, 1046-1055.	0.7	22
241	The controversy about cognitive behavioural therapy for schizophrenia. <i>World Psychiatry</i> , 2019, 18, 235-236.	10.4	22
242	Antipsychotic Dose in Acute Schizophrenia: A Meta-analysis. <i>Schizophrenia Bulletin</i> , 2020, 46, 1439-1458.	4.3	22
243	Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , 2021, 237, 20-25.	2.0	22
244	Results of treatment of schizophrenia: is the glass half full or half empty?. <i>International Clinical Psychopharmacology</i> , 1999, 14, S11-S14.	1.7	21
245	Early symptom response to antipsychotic medication as a marker of subsequent symptom change: An eighteen-month follow-up study of recent episode schizophrenia. <i>Schizophrenia Research</i> , 2012, 141, 168-172.	2.0	21
246	Initial severity and efficacy of risperidone in autism: Results from the RUPP trial. <i>European Psychiatry</i> , 2016, 32, 16-20.	0.2	20
247	Aberrant striatal dopamine links topographically with cortico-thalamic dysconnectivity in schizophrenia. <i>Brain</i> , 2020, 143, 3495-3505.	7.6	20
248	Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 293-302.	3.2	20
249	Monitoring of right ventricular function using a conventional slow response thermistor catheter. <i>Intensive Care Medicine</i> , 1994, 20, 348-353.	8.2	19
250	Perphenazine for schizophrenia. , 2005, , CD003443.		19
251	Psychiatric treatment guidelines: doctors? non-compliance or insufficient evidence?. <i>Acta Psychiatrica Scandinavica</i> , 2007, 115, 417-419.	4.5	19
252	Aripiprazole versus other atypical antipsychotics for schizophrenia. , 2013, , CD006569.		18

#	ARTICLE	IF	CITATIONS
253	Psychometric analysis in support of shortening the Scale for the Assessment of Negative Symptoms. <i>European Neuropsychopharmacology</i> , 2013, 23, 1051-1056.	0.7	18
254	Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials. <i>Schizophrenia Research</i> , 2014, 156, 107-114.	2.0	18
255	Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. <i>BMJ Open</i> , 2017, 7, e016608.	1.9	18
256	Comparative Efficacy and Tolerability of 32 Oral Antipsychotics for the Acute Treatment of Adults With Multi-Episode Schizophrenia: A Systematic Review and Network Meta-Analysis. <i>Focus (American Tj ETQq0 0 OrgBT /Overlock 10 T</i>	0.8	18
257	Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, 2014, CD009230.	2.8	17
258	Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review. <i>BMC Research Notes</i> , 2016, 9, 218.	1.4	17
259	Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100537.	1.1	17
260	Lower cholinergic basal forebrain volumes link with cognitive difficulties in schizophrenia. <i>Neuropsychopharmacology</i> , 2021, 46, 2320-2329.	5.4	17
261	Psychiatrists' decision making between branded and generic drugs. <i>European Neuropsychopharmacology</i> , 2013, 23, 686-690.	0.7	16
262	Schizophrenia, primary negative symptoms, and soft outcomes in psychiatry. <i>Lancet, The</i> , 2017, 389, 1077-1078.	13.7	16
263	Physicians' and Patients' Involvement in Relapse Prevention With Antipsychotics in Schizophrenia. <i>Psychiatric Services</i> , 2005, 56, 1448-1450.	2.0	15
264	Perphenazine for schizophrenia. <i>The Cochrane Library</i> , 2015, 2015, CD003443.	2.8	15
265	Investigation of <i>TSPO</i> variants in schizophrenia and antipsychotic treatment outcomes. <i>Pharmacogenomics</i> , 2015, 16, 5-22.	1.3	15
266	Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study. <i>European Psychiatry</i> , 2021, 64, e7.	0.2	15
267	Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. <i>Lancet Psychiatry,the</i> , 2022, 9, 232-242.	7.4	15
268	How do psychiatrists choose among different antipsychotics?. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 851-854.	1.9	14
269	European psychiatric treatment guidelines: is the glass half full or half empty?. <i>European Psychiatry</i> , 2005, 20, 554-558.	0.2	14
270	Psychiatric Decision Making in the Adoption of a New Antipsychotic in Germany. <i>Psychiatric Services</i> , 2006, 57, 700-703.	2.0	14



#	ARTICLE	IF	CITATIONS
271	Increasing Placebo Response in Antipsychotic Drug Trials: Let's Stop the Vicious Circle. <i>American Journal of Psychiatry</i> , 2013, 170, 1232-1234.	7.2	14
272	Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 187-198.	3.2	14
273	Effects of Genetic Polymorphism in CYP2D6, CYP2C19, and the Organic Cation Transporter OCT1 on Amitriptyline Pharmacokinetics in Healthy Volunteers and Depressive Disorder Patients. <i>Frontiers in Pharmacology</i> , 2021, 12, 688950.	3.5	14
274	Linking the Mini-Mental State Examination, the Alzheimer's Disease Assessment Scale-Cognitive Subscale and the Severe Impairment Battery: evidence from individual participant data from five randomised clinical trials of donepezil. <i>Evidence-Based Mental Health</i> , 2021, 24, 56-61.	4.5	14
275	Language bias in neuroscience—is the Tower of Babel located in Germany?. <i>European Psychiatry</i> , 2004, 19, 230-232.	0.2	13
276	Sertindole versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2009, , CD006752.	2.8	13
277	Attaining and sustaining remission of predominant negative symptoms. <i>Schizophrenia Research</i> , 2013, 143, 60-64.	2.0	13
278	Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 177-86.	2.2	13
279	Maintenance Treatment With Antipsychotic Drugs in Schizophrenia: A Cochrane Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2022, 48, 738-740.	4.3	13
280	The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. <i>European Neuropsychopharmacology</i> , 2013, 23, 1010-1016.	0.7	12
281	Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD009396.	2.8	12
282	Improvement of the physical health of people with mental illness. <i>Current Opinion in Psychiatry</i> , 2006, 19, 411-412.	6.3	11
283	Are all antipsychotic drugs the same?. <i>British Journal of Psychiatry</i> , 2011, 199, 269-271.	2.8	11
284	Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia — data from the OPTiMiSE trial. <i>Psychiatry Research</i> , 2020, 289, 112970.	3.3	11
285	Are Randomized Controlled Trials on Pharmacotherapy and Psychotherapy for Positive Symptoms of Schizophrenia Comparable? A Systematic Review of Patient and Study Characteristics. <i>Schizophrenia Bulletin</i> , 2020, 46, 496-504.	4.3	11
286	Zotepine versus other atypical antipsychotics for schizophrenia. , 2010, , CD006628.		10
287	Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. <i>European Neuropsychopharmacology</i> , 2012, 22, 812-817.	0.7	10
288	Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?. <i>World Psychiatry</i> , 2018, 17, 166-167.	10.4	10

#	ARTICLE	IF	CITATIONS
289	Antipsychotic drugs: from "major tranquilizers" to Neuroscience-based Nomenclature. <i>Psychological Medicine</i> , 2021, 51, 522-524.	4.5	10
290	Multifactorial barriers in the implementation of schizophrenia and psychosocial therapies guidelines: A quantitative study across different professions. <i>Schizophrenia Research</i> , 2021, 228, 425-434.	2.0	10
291	A living meta-ecological study of the consequences of the COVID-19 pandemic on mental health. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 219-221.	3.2	10
292	An efficient way to assess the effect of COVID-19 on mental health in the general population. <i>Lancet Psychiatry</i> , 2021, 8, e14-e15.	7.4	10
293	Which first-generation antipsychotics should be "repurposed" for the treatment of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 1-3.	3.2	10
294	Variability of cerebral blood flow deficits in <sup>99m</sup> Tc-HMPAO SPECT in patients with Alzheimer's disease. <i>Journal of Neural Transmission</i> , 1997, 104, 689-701.	2.8	9
295	Cochrane Schizophrenia Group. <i>Schizophrenia Bulletin</i> , 2007, 34, 259-265.	4.3	9
296	Haloperidol versus chlorpromazine for treatment of schizophrenia. <i>Schizophrenia Bulletin</i> , 2008, 34, 813-815.	4.3	9
297	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. <i>Schizophrenia Research</i> , 2020, 223, 271-278.	2.0	9
298	Optimal Dose of Selective Serotonin Reuptake Inhibitors, Venlafaxine, and Mirtazapine in Major Depression: A Systematic Review and Dose-Response Meta-Analysis. <i>Focus (American Psychiatric Association)</i> , 2010, 18, 101-110.	10.0	10
299	Matrix Metalloproteinase 9 Blood Alterations in Patients With Schizophrenia Spectrum Disorders: A Systematic Review and Meta-Analysis. <i>Schizophrenia Bulletin</i> , 2021, 47, 986-996.	4.3	9
300	Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 774-784.	4.3	9
301	Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs. <i>Pharmacopsychiatry</i> , 2022, 55, 233-245.	3.3	9
302	Are Patients with Schizophrenia Under-treated with Second-generation Antipsychotics? A Pilot Study of the Prescription Practices of German Psychiatrists. <i>Pharmacopsychiatry</i> , 2003, 36, 309-312.	3.3	8
303	Commentary on strategies for switching antipsychotics. <i>BMC Medicine</i> , 2008, 6, 18.	5.5	8
304	Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. <i>Schizophrenia Research</i> , 2015, 164, 122-126.	2.0	8
305	Psychological interventions for positive symptoms in schizophrenia: protocol for a network meta-analysis of randomised controlled trials. <i>BMJ Open</i> , 2018, 8, e019280.	1.9	8
306	Increasing antipsychotic dose for non response in schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011883.	2.8	8

#	ARTICLE	IF	CITATIONS
307	Associations between individual antipsychotics and the risk of arrests and convictions of violent and other crime: a nationwide within-individual study of 74 925 persons. <i>Psychological Medicine</i> , 2022, 52, 3792-3800.	4.5	8
308	Evaluating pimavanserin as a treatment for psychiatric disorders: A pharmacological property in search of an indication. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1651-1660.	1.8	8
309	Vitruvian plot: a visualisation tool for multiple outcomes in network meta-analysis. <i>Evidence-Based Mental Health</i> , 2022, 25, e65-e70.	4.5	8
310	Zotepine versus other atypical antipsychotics for schizophrenia. <i>The Cochrane Library</i> , 2010, , CD006628.	2.8	7
311	Patients' acceptance of the deltoid application of risperidone long-acting injection. <i>European Neuropsychopharmacology</i> , 2012, 22, 897-901.	0.7	7
312	Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD009369.	2.8	7
313	The SWITCH study: rationale and design of the trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 513-521.	3.2	7
314	Enthusiasm and Skepticism About Using National Registers to Analyze Psychotropic Drug Outcomes. <i>JAMA Psychiatry</i> , 2018, 75, 314.	11.0	7
315	Short-acting intramuscular second-generation antipsychotic drugs for acutely agitated patients with schizophrenia spectrum disorders. A systematic review and network meta-analysis. <i>Schizophrenia Research</i> , 2021, 229, 3-11.	2.0	7
316	How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices. <i>Schizophrenia Bulletin</i> , 2022, 48, 27-36.	4.3	7
317	Peroxisome proliferator-activated receptor gamma (PPARG) Pro12Ala: lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine. <i>Molecular Diagnosis and Therapy</i> , 2012, 16, 93-8.	3.8	7
318	Critical trial-related criteria in acute schizophrenia studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 151-155.	3.2	6
319	Clozapine resistanceâ€™ Augmentation strategies. <i>European Neuropsychopharmacology</i> , 2013, 23, 338.	0.7	6
320	Efficacy of antipsychotic drugs for schizophrenia â€™ Authors' reply. <i>Lancet, The</i> , 2013, 382, 1874-1875.	13.7	6
321	A novel approach to measuring response and remission in schizophrenia in clinical trials. <i>Schizophrenia Research</i> , 2017, 190, 123-128.	2.0	6
322	Efficient two-step multivariate random effects meta-analysis of individual participant data for longitudinal clinical trials using mixed effects models. <i>BMC Medical Research Methodology</i> , 2019, 19, 33.	3.1	6
323	Fat Mass and Obesity-Related Gene Variants rs9939609 and rs7185735 are Associated with Second-Generation Antipsychotic-Induced Weight Gain. <i>Pharmacopsychiatry</i> , 2019, 52, 16-23.	3.3	6
324	Antipsychotic drugs <i>v.</i> barbiturates or benzodiazepines used as active placebos for schizophrenia: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 2622-2633.	4.5	6

#	ARTICLE	IF	CITATIONS
325	Examining Side Effect Variability of Antipsychotic Treatment in Schizophrenia Spectrum Disorders: A Meta-analysis of Variance. <i>Schizophrenia Bulletin</i> , 2021, 47, 1601-1610.	4.3	6
326	Should "atypical"™, first-generation antipsychotics no longer be generally used in the treatment of schizophrenia?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1411-1413.	3.2	6
327	Relationship Between Costs and Symptoms in Schizophrenia Patients Treated With Antipsychotic Medication. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 756-765.	2.2	6
328	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , 2022, 9, 291-306.	7.4	6
329	New generation versus conventional antipsychotics. <i>Lancet</i> , 2003, 362, 404-405.	13.7	5
330	Translating research into clinical practice: critical interpretation of clinical trials in schizophrenia. <i>International Clinical Psychopharmacology</i> , 2006, 21, S1-S10.	1.7	5
331	Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?. <i>Acta Psychiatrica Scandinavica</i> , 2014, 130, 40-45.	4.5	5
332	Perazine for schizophrenia. <i>The Cochrane Library</i> , 2014, 2014, CD002832.	2.8	5
333	Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. <i>The Cochrane Library</i> , 2014, , CD009227.	2.8	5
334	Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials. <i>Systematic Reviews</i> , 2021, 10, 214.	5.3	5
335	Linking the Clinical Dementia Rating Scale-Sum of Boxes, the Clinician™s Interview-Based Impression Plus Caregiver Input, and the Clinical Global Impression Scale: Evidence based on Individual Participant Data from Five Randomized Clinical Trials of Donepezil. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 1075-1084.	2.6	5
336	Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in U.S. and International Registries. <i>American Journal of Psychiatry</i> , 2021, 178, 888-889.	7.2	5
337	CATIE Findings Revisited. <i>Psychiatric Services</i> , 2009, 60, 125-126.	2.0	5
338	Early- and subsequent- response of cognitive functioning in Alzheimer's disease: Individual-participant data from five pivotal randomized clinical trials of donepezil. <i>Journal of Psychiatric Research</i> , 2022, 148, 159-164.	3.1	5
339	Benperidol for schizophrenia. <i>The Cochrane Library</i> , 2005, , CD003083.	2.8	4
340	Are new drugs for schizophrenia better than old ones? " Authors' reply. <i>Lancet</i> , 2009, 373, 1249-1250.	13.7	4
341	Accounting for uncertainty due to "last observation carried forward"™ outcome imputation in a meta-analysis model. <i>Statistics in Medicine</i> , 2015, 34, 742-752.	1.6	4
342	Second-generation antipsychotics and quality of life in schizophrenia. <i>Lancet Psychiatry</i> , 2016, 3, 694-695.	7.4	4

#	ARTICLE	IF	CITATIONS
343	Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 210-220.	2.6	4
344	Clozapine in treatment-resistant schizophrenia. <i>British Journal of Psychiatry</i> , 2017, 210, 299-299.	2.8	4
345	Possibly no baseline severity effect for antidepressants versus placebo but for antipsychotics. Why?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 621-623.	3.2	4
346	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. <i>The Cochrane Library</i> , 2018, 5, CD011884.	2.8	4
347	A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 83-94.	3.2	4
348	What is the "best introductory" explanatory versus pragmatic antipsychotic drug trials. <i>Lancet Psychiatry</i> , 2020, 7, 1004-1006.	7.4	4
349	Treatment Goals for Patients with Schizophrenia – A Narrative Review of Physician and Patient Perspectives. <i>Pharmacopsychiatry</i> , 2021, 54, 53-59.	3.3	4
350	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 672-681.	4.3	4
351	The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study. <i>Schizophrenia Research</i> , 2021, 231, 100-107.	2.0	4
352	Imputing the Number of Responders from the Mean and Standard Deviation of CGI-Improvement in Clinical Trials Investigating Medications for Autism Spectrum Disorder. <i>Brain Sciences</i> , 2021, 11, 908.	2.3	4
353	Medical Decision Making in the Mental Health Field. <i>Psychiatric Services</i> , 2005, 56, 221-221.	2.0	4
354	About the issue of including or excluding studies from China in systematic reviews. <i>Schizophrenia Research</i> , 2022, 240, 162-163.	2.0	4
355	Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models. <i>Acta Psychiatrica Scandinavica</i> , 2022, 146, 21-35.	4.5	4
356	What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial. <i>Frontiers in Psychiatry</i> , 2022, 13, 816339.	2.6	4
357	Has Research Informed Us on the Practical Drug Treatment of Schizophrenia?. <i>Schizophrenia Bulletin</i> , 2007, 34, 403-405.	4.3	3
358	Ï Markov model for longitudinal studies with incomplete dichotomous outcomes. <i>Pharmaceutical Statistics</i> , 2017, 16, 122-132.	1.3	3
359	Psychosocial treatments for relapse prevention in schizophrenia: study protocol for a systematic review and network meta-analysis of randomised evidence. <i>BMJ Open</i> , 2020, 10, e035073.	1.9	3
360	Treatment Approaches for First Episode and Early-Phase Schizophrenia in Adolescents and Young Adults: A Delphi Consensus Report from Europe. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 201-219.	2.2	3

#	ARTICLE	IF	CITATIONS
361	Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis. Therapeutic Advances in Psychopharmacology, 2022, 12, 204512532210972.	2.7	3
362	Perazine for schizophrenia. , 2006, , CD002832.		2
363	Different antipsychotics produce similar, small improvements in psychosocial functioning at one year in people with schizophrenia. Evidence-Based Mental Health, 2007, 10, 112-112.	4.5	2
364	Pretrial Medication Bias in Randomized Antipsychotic Drug Trials. American Journal of Psychiatry, 2007, 164, 1266-1266.	7.2	2
365	Issues in Psychopharmacology. Schizophrenia Bulletin, 2007, 34, 258-258.	4.3	2
366	Ventajas y desventajas del tratamiento de combinaci3n con antipsic3ticos. Reuni3n ECNP Consensus, marzo de 2008, Niza. Psiquiatria Biologica, 2011, 18, 55-67.	0.1	2
367	Drowning in Numbersâ€“what Psychiatrists Mean when Talking to Patients about Probabilities of Risks and Benefits of Medication. European Psychiatry, 2011, 26, 130-131.	0.2	2
368	Increasing antipsychotic dose for non response in schizophrenia. The Cochrane Library, 0, , .	2.8	2
369	Increasing antipsychotic dose versus switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	2.8	2
370	31.3 CLINICAL UTILITY OF MRI SCANNING IN FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S50-S51.	4.3	2
371	Antipsychotic Medications: Enhancing Use to Improve Outcomes. Schizophrenia Bulletin, 2021, 47, 1201-1204.	4.3	2
372	Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. The Cochrane Library, 0, , .	2.8	2
373	Baseline levels of C-reactive protein and proinflammatory cytokines are not associated with early response to amisulpride in patients with First Episode Psychosis: the OPTiMiSE cohort study. Schizophrenia Bulletin Open, 0, , .	1.7	2
374	Behandlungsresistenz. , 2016, , 157-176.		2
375	Reply to The Importance of Negative Comorbidity. Journal of Clinical Psychiatry, 2009, 70, 1192.	2.2	2
376	An update of meta-analyses on second-generation antipsychotic drugs for schizophrenia. Medical Psychiatry, 2009, , 164-173.	0.2	2
377	Schizophrenien und andere psychotische St4rungen. , 2012, , 347-419.		2
378	New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment. Schizophrenia Research, 2022, 239, 192-199.	2.0	2

#	ARTICLE	IF	CITATIONS
379	Cognitive impairment networks in Alzheimer's disease: Analysis of three double-blind randomized, placebo-controlled, clinical trials of donepezil. <i>European Neuropsychopharmacology</i> , 2022, 57, 50-58.	0.7	2
380	Concept of the Munich/Augsburg Consortium Precision in Mental Health for the German Center of Mental Health. <i>Frontiers in Psychiatry</i> , 2022, 13, 815718.	2.6	2
381	Evidence-based Shared-Decision-Making Assistant (SDM-assistant) for choosing antipsychotics: protocol of a cluster-randomized trial in hospitalized patients with schizophrenia. <i>BMC Psychiatry</i> , 2022, 22, .	2.6	2
382	Dr. Correll and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2005, 162, 405-a-406.	7.2	1
383	The Dopamine D4 Receptor 48 Base Pair Repeat Polymorphism Influences Antipsychotic Induced Body Weight Gain. A Preliminary Report. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 242.	2.0	1
384	Poster #216 IS HALOPERIDOL MORE EFFECTIVE THAN OTHER FIRST-GENERATION ANTIPSYCHOTICS IN SCHIZOPHRENIA? A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. <i>Schizophrenia Research</i> , 2012, 136, S263-S264.	2.0	1
385	Evidence-based pharmacotherapy of schizophrenia. , 0, , 18-38.		1
386	Comparative Efficacy and Tolerability of 15 Antipsychotic Drugs in Schizophrenia: A Multiple-Treatments Meta-Analysis. <i>Focus (American Psychiatric Publishing)</i> , 2014, 12, 192-204.	0.8	1
387	The Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial: Rationale for Its Methodology and a Review of the Effectiveness of Switching Antipsychotics. <i>Focus (American J</i>	0.8	1
388	DSM-III-R change in definition might have affected placebo response to antidepressants – Authors' reply. <i>Lancet Psychiatry</i> , 2017, 4, 22-23.	7.4	1
389	Clozapine versus olanzapine for people with schizophrenia. <i>The Cochrane Library</i> , 2018, , .	2.8	1
390	Optimal dosing of antidepressant drugs – Authors' reply. <i>Lancet Psychiatry</i> , 2019, 6, 806-807.	7.4	1
391	Antipsychotics for schizophrenia and substance misuse – Authors' reply. <i>Lancet</i> , 2020, 395, 1903.	13.7	1
392	Quantifying the heterogeneity of cognitive functioning in Alzheimer's disease to extend the placebo-treatment dichotomy: Latent class analysis of individual-participant data from five pivotal randomized clinical trials of donepezil. <i>European Psychiatry</i> , 2021, 64, e16.	0.2	1
393	Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. <i>The Cochrane Library</i> , 0, , .	2.8	1
394	Schizophrenien und andere psychotische Störungen. , 2009, , 411-490.		1
395	Schizophrenien und andere psychotische Störungen. , 2019, , 301-362.e7.		1
396	Cognitive behavioural therapy plus standard care for first episode psychosis. <i>The Cochrane Library</i> , 2022, 2022, .	2.8	1

#	ARTICLE	IF	CITATIONS
397	Rapid Detection Of The Intermediate Metabolizer Associated CYP2D6 Polymorphisms *9 And *17 With Real Time PCR. Therapeutic Drug Monitoring, 2005, 27, 242-243.	2.0	0
398	Intermediate Metabolizers And Increased Risk Of Adverse Events in Psychiatric In-patients. an Update Including All Relevant Alleles With Reduced Function and Applying Gene-dose for Analysis. Therapeutic Drug Monitoring, 2005, 27, 254-255.	2.0	0
399	Is there a differential efficacy of new generation antipsychotic drugs?. International Journal of Psychiatry in Clinical Practice, 2005, 9, 154-156.	2.4	0
400	Dr. Hamann and Colleagues Reply. American Journal of Psychiatry, 2006, 163, 937-937.	7.2	0
401	Eleven-year clinical outcome of schizophrenia in Bali. Acta Psychiatrica Scandinavica, 2006, 114, 68-68.	4.5	0
402	Intramuscular haloperidol and olanzapine begin to reduce psychosis within 24 hours. Evidence-Based Mental Health, 2006, 9, 9-9.	4.5	0
403	Quetiapine is no less effective than risperidone for reducing symptoms of schizophrenia. Evidence-Based Mental Health, 2007, 10, 56-56.	4.5	0
404	Review: little evidence to support dose escalation of selective serotonin reuptake inhibitors in non-responders. Evidence-Based Mental Health, 2007, 10, 46-46.	4.5	0
405	Methylenedioxymethamphetamine (MDMA). , 2010, , 758-762.		0
406	Movement Disorder. , 2010, , 805-805.		0
407	Antipsychotic drugs for relapse prevention in schizophrenia â€œ Authors' reply. Lancet, The, 2012, 380, 1056.	13.7	0
408	PHARMACOLOGICAL AUGMENTATION STRATEGIES FOR SCHIZOPHRENIA PATIENTSWITH INSUFFICIENT RESPONSE TO CLOZAPINE. Schizophrenia Research, 2012, 136, S21.	2.0	0
409	META-ANALYSIS ON RELAPSE PREVENTION WITH ANTIPSYCHOTIC DRUGS COMPARED TO PLACEBO IN SCHIZOPHRENIA. Schizophrenia Research, 2012, 136, S58.	2.0	0
410	Can we inflate effect size and thus increase chances of producing â€œpositiveâ€œ results if we raise the baseline threshold in schizophrenia trials?. Schizophrenia Research, 2013, 144, 105-108.	2.0	0
411	Bipolar treatment efficacy â€œ Authors' reply. Lancet Psychiatry,the, 2014, 1, 418-419.	7.4	0
412	META-ANALYSES ON DOUBLE-BLIND RCTS ADDING DRUGS WITH ANTI-INFLAMMATORY PROPERTIES TO ANTIPSYCHOTIC MEDICATION. Schizophrenia Research, 2014, 153, S15-S16.	2.0	0
413	Switching antipsychotic for non response in schizophrenia. The Cochrane Library, 2015, , .	2.8	0
414	Authors' reply. British Journal of Psychiatry, 2016, 209, 171-172.	2.8	0



#	ARTICLE	IF	CITATIONS
415	Use of Clozapine in Schizophreniaâ€”Reply. JAMA Psychiatry, 2016, 73, 1098.	11.0	0
416	Clozapine versus quetiapine for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	0
417	Clozapine versus risperidone for people with schizophrenia. The Cochrane Library, 2018, , .	2.8	0
418	S47. ADD-ON SPIRONOLACTONE FOR THE TREATMENT OF SCHIZOPHRENIA (SPIRO TREAT). Schizophrenia Bulletin, 2018, 44, S342-S342.	4.3	0
419	17.1 PREDICTORS OF RELAPSE IN FIRST EPISODE PSYCHOSIS PATIENTS IN REMISSION. Schizophrenia Bulletin, 2019, 45, S115-S116.	4.3	0
420	17.4 STRATIFICATION AND PREDICTION OF REMISSION IN FIRST-EPISODE PSYCHOSIS PATIENTS: THE OPTIMISE COHORT STUDY. Schizophrenia Bulletin, 2019, 45, S116-S117.	4.3	0
421	M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA â€” A META-REGRESSION ANALYSIS. Schizophrenia Bulletin, 2020, 46, S212-S213.	4.3	0
422	Gauging the Scope for Precision Medicine: Evaluating Individual Differences in Side Effects to Antipsychotic Treatment. Biological Psychiatry, 2020, 87, S291-S292.	1.3	0
423	T200. METABOLIC SIDE EFFECTS OF ANTIPSYCHOTIC DRUGS â€” PROTOCOL OF A SYSTEMATIC REVIEW AND NETWORK- METAANALYSIS. Schizophrenia Bulletin, 2020, 46, S308-S308.	4.3	0
424	Let us not rush back to odds ratios without a recommendation to convert them to interpretable measures. Journal of Clinical Epidemiology, 2021, 134, 172-173.	5.0	0
425	Dr. Hamann and Colleagues Reply. Journal of Clinical Psychiatry, 2008, 69, 326-327.	2.2	0
426	Therapieresistente Schizophrenie (ICD-10 F2). , 2009, , 117-130.		0
427	SpÃ¤tschizophrenie und chronische Schizophrenie im hÃ¶heren Lebensalter. , 2011, , 241-262.		0
428	Schizophrenien und andere psychotische StÃ¶rungen. , 2015, , 349-412.		0
429	Evidenzbasierung und leitliniengestÃ¼tzte Therapie in der Psychiatrie. , 2016, , 1-18.		0
430	Evidenzbasierung und leitliniengestÃ¼tzte Therapie in der Psychiatrie. , 2017, , 1321-1338.		0
431	In Reply. Deutsches A&#x0308;rzteblatt International, 2018, 115, 68-69.	0.9	0
432	Limitations in Research on Maintenance Treatment for Individuals With Schizophreniaâ€”Reply. JAMA Psychiatry, 2021, , .	11.0	0

#	ARTICLE	IF	CITATIONS
433	How long do psychiatrists wait for response before they switch to another antipsychotic?. Psychopharmacology Bulletin, 2007, 40, 149-54.	0.0	0
434	Relapse prevention in schizophrenia – Authors' reply. Lancet Psychiatry,the, 2022, 9, e14.	7.4	0
435	Confidence of evidence should be considered in ranking of treatments in the network meta-analysis – Authors' reply. Lancet Psychiatry,the, 2022, 9, e16.	7.4	0